Investors & Media

Investors

News & Press Releases

August 14, 2025

SEED Therapeutics Named Finalist for 2025 Prix Galien USA “Best Start-Up” Award

August 11, 2025

FDA Clears IND for SEED Therapeutics’ RBM39 Degrader ST-01156

June 9, 2025

SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer

May 5, 2025

SEED Therapeutics Highlights Breakthrough Advances in Targeted Protein Degradation at AACR 2025

April 24, 2025

SEED Therapeutics Reports Breakthroughs for Two Targeted Protein Degradation Projects at AACR Annual Meeting in Chicago

January 28, 2025

SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors

Presentations & Publications

Presentations

Transforming Undruggable Targets into Therapeutics

American Association for Cancer Research 2025 Poster – Targeting Ewing Sarcoma with A Novel RBM39 Degrader

American Association for Cancer Research 2025 Poster: Combinational Use of VHL and KEAP1-based PROTACs

2023 TPD Think Tank Symposium

Publications

Nature Biopharma Dealmakers Article, June 2023

Nature Reviews Drug Discovery Article, October 2024

Nature Biotechnology Publication, March 2024